1.80
0.06 (3.45%)
| Previous Close | 1.74 |
| Open | 1.74 |
| Volume | 2,242,658 |
| Avg. Volume (3M) | 2,359,432 |
| Market Cap | 531,324,000 |
| Price / Earnings (Forward) | 9.14 |
| Price / Sales | 253.17 |
| Price / Book | 7.25 |
| 52 Weeks Range | |
| Earnings Date | 14 Aug 2025 |
| Operating Margin (TTM) | -1,685.01% |
| Diluted EPS (TTM) | -0.550 |
| Quarterly Revenue Growth (YOY) | 25.90% |
| Total Debt/Equity (MRQ) | 35.04% |
| Current Ratio (MRQ) | 3.53 |
| Operating Cash Flow (TTM) | -70.41 M |
| Levered Free Cash Flow (TTM) | -53.20 M |
| Return on Assets (TTM) | -44.04% |
| Return on Equity (TTM) | -278.55% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Precigen, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | 3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 2.5 |
| Average | 2.70 |
|
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.56% |
| % Held by Institutions | 67.08% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Iridian Asset Management Llc/Ct | 31 Dec 2024 | 5,241,922 |
| Lexaurum Advisors, Llc | 31 Dec 2024 | 691,544 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 8.50 (HC Wainwright & Co., 372.22%) | Buy |
| Median | 8.25 (358.33%) | |
| Low | 8.00 (JMP Securities, 344.44%) | Buy |
| Average | 8.25 (358.33%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 3.22 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 19 Aug 2025 | 8.50 (372.22%) | Buy | 3.22 |
| 15 Aug 2025 | 8.50 (372.22%) | Buy | 2.94 | |
| JMP Securities | 19 Aug 2025 | 8.00 (344.44%) | Buy | 3.22 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AGEE NANCY H | 4.56 | - | 15,000 | 68,400 |
| Aggregate Net Quantity | 15,000 | |||
| Aggregate Net Value ($) | 68,400 | |||
| Aggregate Avg. Buy ($) | 4.56 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| AGEE NANCY H | Director | 04 Sep 2025 | Buy (+) | 15,000 | 4.56 | 68,400 |
| Date | Type | Details |
|---|---|---|
| 03 Sep 2025 | Announcement | Precigen Announces Up to $125 Million Non-Dilutive Financing |
| 25 Aug 2025 | Announcement | Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright |
| 15 Aug 2025 | Announcement | Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |